MedSIR EXPANDS INTO NEW TUMOR TYPES AT ESMO 2017
At MedSIR we are widely known for our extensive work in Breast Cancer, however, at ESMO 2017 in Madrid, Spain, we gave the Oncology world a glimpse of our desire to expand into new tumor types through the presentation of two posters; the SLLIP Study and the EXCAAPE Study.
The objective of the Lung Cancer SLLIP (Spanish Lung Liquid vs. Invasive biopsy Program Evaluation) Study is to investigate cfDNA-based versus tissue-based genotyping as it pertains to the detection of clinically actionable biomarkers in first line, treatment naïve, metastatic non-squamous NSCLC. Accrual has terminated and final results should be presented in 2018.
The EXCAAPE trial is ongoing and actively enrolling patients in 12 centers across Spain. The goal of this study is to assess the activity of Radium-223 in patients with metastatic castration-resistant prostate cancer with asymptomatic progression while on abiraterone or enzalutamide, while also looking into the patient’s AR-V7 mutational status. The poster exposed the trial design and results should be ready to present sometime late 2018 or earl 2019.